Abstract

Gingipains are protease virulence factors produced by Porphyromonas gingivalis, a Gram-negative bacterium best known for its role in chronic periodontitis. Gingipains were recently identified in the middle temporal gyrus of postmortem Alzheimer’s disease (AD) brains, where gingipain load correlated with AD diagnosis and tau and ubiquitin pathology. Since AD and Parkinson’s disease (PD) share some overlapping pathologic features, including nigral pathology and Lewy bodies, the current study explored whether gingipains are present in the substantia nigra pars compacta of PD brains. In immunohistochemical techniques and multi-channel fluorescence studies, gingipain antigens were abundant in dopaminergic neurons in the substantia nigra of both PD and neurologically normal control brains. 3-dimensional reconstructions of Lewy body containing neurons revealed that gingipains associated with the periphery of alpha-synuclein aggregates but were occasionally observed inside aggregates. In vitro proteomic analysis demonstrated that recombinant alpha-synuclein is cleaved by lysine-gingipain, generating multiple alpha-synuclein fragments including the non-amyloid component fragments. Immunogold electron microscopy with co-labeling of gingipains and alpha-synuclein confirmed the occasional colocalization of gingipains with phosphorylated (pSER129) alpha-synuclein. In dopaminergic neurons, gingipains localized to the perinuclear cytoplasm, neuromelanin, mitochondria, and nucleus. These data suggest that gingipains localize in dopaminergic neurons in the substantia nigra and interact with alpha-synuclein.

Details

Title
Ultrastructural localization of Porphyromonas gingivalis gingipains in the substantia nigra of Parkinson’s disease brains
Author
Ermini, Florian 1   VIAFID ORCID Logo  ; Low, Victoria F. 2 ; Song, Jennifer J. 2 ; Tan, Adelie Y. S. 2 ; Faull, Richard L. M. 2 ; Dragunow, Michael 3   VIAFID ORCID Logo  ; Curtis, Maurice A. 2   VIAFID ORCID Logo  ; Dominy, Stephen S. 4 

 Inc., Previously Cortexyme, South San Francisco, USA; Stanford University, Department of Bioengineering, Stanford, USA (GRID:grid.168010.e) (ISNI:0000 0004 1936 8956) 
 The University of Auckland, NeuroValida, Auckland, New Zealand (GRID:grid.9654.e) (ISNI:0000 0004 0372 3343); The University of Auckland, Department of Anatomy and Medical Imaging, Auckland, New Zealand (GRID:grid.9654.e) (ISNI:0000 0004 0372 3343) 
 The University of Auckland, NeuroValida, Auckland, New Zealand (GRID:grid.9654.e) (ISNI:0000 0004 0372 3343); The University of Auckland, Department of Pharmacology and Clinical Pharmacology, Auckland, New Zealand (GRID:grid.9654.e) (ISNI:0000 0004 0372 3343) 
 Inc., Previously Cortexyme, South San Francisco, USA (GRID:grid.9654.e); Stanford University, Department of Bioengineering, Stanford, USA (GRID:grid.168010.e) (ISNI:0000 0004 1936 8956); Inc., Lighthouse Pharmaceuticals, San Francisco, USA (GRID:grid.168010.e) 
Pages
90
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
23738057
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3046095827
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.